A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Inavolisib|DRUG: Phesgo|DRUG: Placebo|DRUG: Taxane-based Chemotherapy|DRUG: Optional Endocrine Therapy of Investigator's Choice
Sponsor: Hoffmann-La Roche